Mid-stage CNS biotech Alto Neuroscience plots $89M IPO
Alto Neuroscience joined Fractyl Health in outlining its IPO price range on Monday morning as the two biotechs look to build on the momentum generated by CG Oncology and ArriVent Biopharma last week.
The mid-stage CNS biotech plans to raise about $89 million in IPO proceeds if it prices at the midpoint of its proposed $14 to $16 range. Alto expects to sell 6.7 million shares $ANRO in its debut on the NYSE, likely later this week. Most biotech startups list on the Nasdaq, but the NYSE has been attempting to grow its life sciences roster in recent years.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.